Galapagos' CEO makes donation of €10 million in the form of personal shares to African ParksGlobeNewsWire • 12/23/20
Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls ApartInvestors Business Daily • 12/16/20
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)Business Wire • 12/15/20
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) GlobeNewsWire • 12/15/20
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney diseaseGlobeNewsWire • 12/01/20
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial GlobeNewsWire • 11/30/20
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosisGlobeNewsWire • 11/05/20
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative ColitisBusiness Wire • 11/02/20
Galapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 10/18/20
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOsBenzinga • 10/16/20
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patientsGlobeNewsWire • 10/15/20
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative ColitisBusiness Wire • 10/12/20
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trialGlobeNewsWire • 09/29/20